Introduction
============

Pancreatic duct cells not only deliver the enzymes produced by acinar cells into duodenum but also secrete a HCO~3~^-^-rich fluid to neutralize gastric acid from the stomach.[@R1] Tight junctions of the pancreatic duct are regulators of physiologic secretion of the pancreas and disruption of the pancreatic ductal barrier. The tight junction, the most apically located of the intercellular junctional complexes, inhibits solute and water flow through the paracellular space (termed the "barrier" function).[@R2]^,^[@R3] It also separates the apical from the basolateral cell surface domains to establish cell polarity (termed the "fence" function).[@R4]^,^[@R5] Tight junctions participate in signal transduction mechanisms that regulate epithelial cell proliferation, gene expression, differentiation and morphogenesis.[@R6] The tight junction is formed by not only the integral membrane proteins claudins, occludin and JAMs, but also many peripheral membrane proteins.[@R7]^-^[@R9] These tight junction proteins are regulated by various cytokines and growth factors via distinct signal transduction pathways.[@R10]^,^[@R11] Normal ductal and acinar structures of the pancreas express claudin-1, -2, -3, -4 and -7, whereas endocrine cells within the islets of Langerhans express claudin-3 and -7.[@R12]^,^[@R13] In the pancreatic duct, freeze-fracture analysis reveals that tight junctions contained a parallel array of three to five continuous sealing strands and the pancreatic enzymes cannot leak out from the lumen into the intercellular spaces.[@R14]^,^[@R15]

Pancreatic ductal tight junctions, which is leaky and has the function of selective permeability, may play a role of channels of Na^+^ and HCO~3~^-^ via paracellular pathway.[@R16]^,^[@R17] The tight junctions of pancreatic duct epithelial cells and exocrine cells are dynamic structures that can be disrupted by various external stimuli including ductal hypertension.[@R18]^,^[@R19] The disruption of pancreatic duct tight junctions is an early event in different types of pancreatitis.[@R20]^-^[@R25] Although dysfunction of tight junctions in pancreatic duct are observed by various pathological condition, the regulatory mechanisms of tight junctions remain unknown even in normal human pancreatic duct epithelial (HPDE) cells.

On the other hand, in pancreatic cancer, claudin-4 and -18 are highly expressed and are diagnostic or therapeutic targets of monoclonal antibodies against their extracellular loops.[@R26]^-^[@R28] Both the abundance and the subcellular distribution of specific claudin proteins are different between normal and transformed pancreatic epithelia and the changes in paracellular permeability accompany the formation of pancreatic intraepithelial neoplasia (PanIN).[@R29] The claudin family, which consists of at least 27 members, is solely responsible for forming tight junction strands and has four transmembrane domains and two extracellular loops.[@R7]^,^[@R30] The first extracellular loop is the coreceptor of hepatitis C virus and influences the paracellular charge selectivity and the second extracellular loop is the receptor of *Clostridium perfringens* enterotoxin (CPE).[@R31]^-^[@R33] The 35-kDa polypeptide CPE causes food poisoning in humans, binds to its claudin receptor and then causes changes in membrane permeability via formation of a complex on the plasma membrane followed by the induction of apoptosis.[@R34] In pancreatic cancer, claudin-4 is frequently overexpressed and is a high-affinity receptor of CPE.[@R27]^,^[@R35] It is anticipated that it may be possible to develop a novel tumor-targeted therapy for pancreatic cancer using a claudin-4-targeting molecule.

This review focuses on recent our findings about the relationship between tight junctions and signal transduction pathways in normal human pancreatic duct epithelial cells, using hTERT-transfected human pancreatic epithelial cells ([Table 1](#T1){ref-type="table"}).

###### **Table 1.** Changes of tight junction proteins and barrier function in normal human pancreatic duct epithelial cells via PKC and JNK pathways

  ------------------------------------------------------------------------------------------------------------------------------
  Cell type               Treatment                             Tight junction proteins          Barrier function   Ref.
  ----------------------- ------------------------------------- -------------------------------- ------------------ ------------
                          **FBS**                               **CLDN-1, -4, -7 ↑; OCLN ↑;**\   **upregulation**   **13**
                                                                **ZO-1, -2 ↑**                                      

  **PKC activator:TPA**   **CLDN-1, -4, -7, -18 ↑; OCLN ↑;**\                                    **13, 45**         
                          **ZO-1, -2 ↑**                                                                            

  **hTERT-**\             **PKCa inhibitor:Gö6976**             **CLDN-1, -4, -7 ↑; OCLN ↑**     **upregulation**   **54, 55**
  **HPDE**                                                                                                          

                          **JNK activator:Anisomycin**\         **TRIC ↑**                                          **60**
                          **:IL-1b, TNFa, IL-1a**                                                                   

                          **JNK inhibitor:SP600125**            **CLDN-1, -4, -7 ↑; OCLN ↑;**\   **upregulation**    
                                                                **MarvelD3 ↑; TRIC ↓**                              
  ------------------------------------------------------------------------------------------------------------------------------

hTERT-HPDE, hTERT-transfected human pancreatic duct epithelial cells; CLDN, claudin; OCLN, occludin; TRIC, tricelllulin.

Tight Junction Molecules of hTERT-HPDE Cells
============================================

The introduction of the catalytic subunit of human telomerase, human telomerase reverse transcriptase (hTERT), into human somatic cells such as fibroblasts and retinal pigment epithelial cells typically extends their lifespan without altering their growth requirements, disturbance of the cell-cycle checkpoints, tumorigenicity or chromosomal abnormalities.[@R36]^-^[@R38] We established hTERT-transfected human pancreatic epithelial cells (hTERT-HPDE) with an extended life span.[@R13]

The hTERT-HPDE cells are positive for HPDE cell markers such as CK7, CK19 and carbonic anhydrase isozyme 2 (CA-II) and express epithelial tight junction molecules claudin-1, -4, -7 and -18, occludin, tricellulin, marvelD3, JAM-A, ZO-1 and ZO-2.[@R13] The expression patterns of tight junction molecules in the hTERT-HPDE cells are similar to those of pancreatic tissues in vivo.[@R13]

Induction of Tight Junction Molecules and the Barrier Function by FBS in hTERT-HPDE Cells
=========================================================================================

In this culture system, hTERT-HPDE cells in serum-free conditioned medium have growth potential and a long lifespan. Treatment with FBS induces an increase of protein and mRNA of CA-II dependent on the FBS concentration, whereas proteins of CK7 and CK19 are stably expressed independent of the FBS concentration. Claudin-1, -4 and -7, occludin, JAM-A and ZO-1, -2 are induced together with an increase of the barrier function by 10% FBS and the upregulation is inhibited by the pan-PKC inhibitor GF109203X ([Table 1](#T1){ref-type="table"}).[@R13] The tight junction molecules and the barrier function induced by FBS in hTERT-HPDE cells are in part regulated via a PKC pathway.

Barrier Function of hTERT-HPDE Cells and Pancreatic Cancer Cell Lines
=====================================================================

In immunocytochemistry, occludin which is a good marker of tight junction position, is localized at the cell membranes of hTERT-HPDE cells with 10% FBS and pancreatic cancer cell lines PANC-1 and BXPC3 (poorly differentiated types), HPAF-II and HPAC (moderately or well-differentiated types), whereas in hTERT-HPDE cells without FBS, it is not detected at the membranes ([Fig. 1A](#F1){ref-type="fig"}). When the barrier function was measured by transepithelial electrical resistance (TER) values, the barrier function in hTERT-HPDE cells with 10% FBS was well maintained as well-diffrentiated pancreatic cancer cells HPAF-II and HPAC ([Fig. 1B](#F1){ref-type="fig"}). The barrier function in the pancreatic duct may be independent on the localization of occludin.

![**Figure 1.(A)** Immunostaining for occludin and **(B)** TER values in hTERT-HPDE cells with or without 10% FBS and pancreatic cancer cell lines PANC-1, BXPC-3, HPAF-II and HPAC. Bars: 40 μm. Data represent the mean (n = 6). **(C)** A line graph for the changes in proteins of claudin-1, -4 and -7 in hTERT-HPDE cells treated with 100 nM TPA. **(D)** Diagram showing regulation of tight junction molecules via PKC isoforms in hTERT-HPDE cells. CLDN: claudin, OCLN: occludin.](tisb-1-e24894-g1){#F1}

It is thought that normal HPDE cells are sealed well by tight junctions and the tight junctions play a crucial role in the reflux of the exocrine pancreatic juice. The barrier function of well-diffrentiated pancreatic cancer cells is well maintained compared with poorly differentiated pancreatic cancer cells.

Regulation of Tight Junction Molecules by a PKC Activator in hTERT-HPDE Cells
=============================================================================

Protein kinase C (PKC) is a family of serine-threonine kinases known to regulate epithelial barrier function via tight junctions.[@R39]^,^[@R40] PKC has been shown to induce both assembly and disassembly of tight junctions depending on the cell type and conditions of activation.[@R40]^-^[@R42] PKC activation can readily disrupt the integrity of pancreatic epithelial tight junctions by causing ROCK-II dependent actomyosin-driven contractility or remodeling of the spectrin-adducin based membrane skeleton.[@R43]^,^[@R44]

When hTERT-HPDE cells are treated with the PKC activator 12-O-tetradecanoylphorbol 13-acetate (TPA), claudin-1, -4, -7 and -18, occludin, JAM-A and ZO-1, -2 are increased and the upregulation is inhibited by the pan-PKC inhibitor GF109203X ([Table 1](#T1){ref-type="table"}).[@R13]^,^[@R45]

It is thought that claudins are regulated by various factors and that there is differential regulation among claudin family members.[@R9]^,^[@R39]^,^[@R40] When we investigated the time-dependent changes in proteins of claudin-1, -4 and -7 in hTERT-HPDE cells after treatment with TPA, claudin-1 was increased from 1 h, claudin-4 was increased from 3 h, and claudin-7 was increased from 12 h ([Fig. 1C](#F1){ref-type="fig"}).

We investigated which PKC isoforms play key roles in the upregulation of tight junction proteins by TPA in hTERT-HPDE cells. The upregulation of tight junction proteins by TPA was inhibited completely by a pan-PKC inhibitor (GF109203X). A PKCθ inhibitor (myristoylated PKCθ pseudosubstrate peptide inhibitor) prevented upregulation of claudin-18 by TPA, a PKCα inhibitor (Gö6976) prevented upregulation of claudin-4 and -18 by TPA, and a PKCδ inhibitor (rottlerin) prevented upregulation of claudin-7, -18, occludin, ZO-1 and ZO-2 by TPA ([Fig. 1D](#F1){ref-type="fig"}).

By GeneChip analysis of hTERT-HPDE cells treated with or without TPA, upregulation of one of the ELF (E74-like factor) subfamily of the ETS transcription factors ELF3 was observed.[@R13] It is reported that the expression of claudin-7 in epithelial structures in synovial sarcoma is regulated by ELF3.[@R46] In hTERT-HPDE cells, ELF3 mRNA is increased by TPA and a pan-PKC inhibitor prevents upregulation of ELF3 mRNA by TPA and the upregulation of claudin-7 by TPA is inhibited by knockdown of ELF3 using siRNAs.[@R13] These results suggest that claudin-7 in normal HPDE cells might be regulated via a PKCδ/ELF-3 pathway.

We previously reported that the regulation of tight junctions in normal ductal epithelial cells was closely associated with conventional or novel isoforms of PKC and PKC-induced transcriptional factors.[@R47]^,^[@R48] PKC may be a useful target for pancreatic cancer therapy.[@R49] Further study of the tight junctions of normal HPDE cells via a PKC pathway including isoforms is important for not only physiological regulation of tight junction molecules and the barrier function in normal HPDE cells but also for therapeutic targeting in pancreatic cancer cells.

Regulation of Tight Junction Molecules and the Barrier Function by a PKCα Inhibitor in hTERT-HPDE Cells
=======================================================================================================

At least 12 different isozymes of PKC are known and can be subdivided into three classes (classic or conventional, novel and atypical isozymes) according to their responsiveness to activators.[@R50] In the human intestinal epithelial cell lines HT-29 and Caco-2, stimulation with TLR2 ligands leads to activation of the specific PKC isoforms PKCα and PKCδ and enhances barrier function through translocation of ZO-1 on activation.[@R51] PKCα is considered one of the biomarkers for the diagnosis of cancers, including pancreatic cancer.[@R52]^,^[@R53] We previously reported that the PKCα inhibitor Gö6976 modified claudin-1 and -4 in a well-differentiated pancreatic cancer cell line.[@R54] When hTERT-HPDEs were treated with Gö6976, expression of claudin-1, -4, -7 and occludin, and the barrier function measured as TER values, were significantly increased ([Table 1](#T1){ref-type="table"}).[@R55] The TGF-β-PKC-α-PTEN cascade is a key pathway for pancreatic cancer cells to proliferate and metastasize.[@R56] PKCα inhibitors may be potential therapeutic agents against the malignancy of human pancreatic cancer cells.[@R57]

Regulation of Rricellulin by JNK Activators in hTERT-HPDE Cells
===============================================================

c-Jun N-terminal kinase (JNK) activation is essential for disassembly of adherens and tight junctions in human keratinocytes and colonic epithelial cells.[@R58]^,^[@R59] When hTERT-HPDE cells are treated with JNK activators, anisomycin and the proinflammatory cytokines IL-1β, TNFα and IL-1α, only tricellulin expression is significantly increased by all JNK activators, and the upregulation was prevented by the JNK inhibitor SP600125 ([Table 1](#T1){ref-type="table"}).[@R60]

Tricellulin was identified as the first marker of the tricellular tight junction, which forms at the meeting points of three cells. It is required for the maintenance of the transepithelial barrier and expressed in both the normal pancreatic duct and pancreatic cancer.[@R61]^-^[@R63] It is one of three members of the tight junction-associated MARVEL protein family (TAMP) and is specific to tricellular tight junctions, whereas the other two members, occludin and marveld3, are localized at bicellular tight junctions.[@R61]^,^[@R64]^,^[@R65] It is possible that the regulation of tricellulin may be more sensitive to the activation of JNK than that of bicellular tight junction proteins in normal HPDE cells.

Regulation of Tight Junction Molecules and the Barrier Function by a JNK Inhibitor in hTERT-HPDE Cells
======================================================================================================

Recently, it was reported that the JNK inhibitor SP600125 enhanced epithelial barrier function through differential modulation of claudin expression in murine mammary epithelial cells.[@R66] When hTERT-HPDE cells were treated with 10 μM JNK inhibitor SP600125 for 24 h, the cells in phase-contrast images rapidly changed from a cobblestone appearance to a round shape ([Fig. 2A](#F2){ref-type="fig"}). This change was similar to that in FBS- or TPA-treated cells.[@R13] In hTERT-HPDE cells after treatment with 10 μM SP600125, claudin-1, -4, occludin and marvelD3 were increased, whereas tricellulin was decreased ([Fig. 2B](#F2){ref-type="fig"}). The barrier function measured by the TER values were increased in a time-dependent manner after treatment with 10 μM SP600125 ([Fig. 2C](#F2){ref-type="fig"}).

![**Figure 2.(A)** Phase-contrast images of hTERT-HPDE cells treated with 10 μM SP600925. Bar: 40 μm. **(B)** Western blotting for claudin-1, -4 and -7, OCLN, TRIC, MARVELD3 and E-cadherin in hTERT-HPDE cells treated with 10 μM SP600925. **(C)** TER values of hTERT-HPDE cells treated with 10 μM SP600925. Data represent the mean ± SD (n = 3). CLDN: claudin, OCLN: occludin, TRIC: tricellulin.](tisb-1-e24894-g2){#F2}

Activation of JNK promotes developments of various tumors.[@R67]^-^[@R69] JNK1-deficient mice exhibits a decrease in carcinogenesis of chemical induced gastric cancer or hepatocellular carcinoma, and JNK2-deficient mice shows reduced skin tumors.[@R70]^-^[@R72] Furthermore, JNK inhibitors decrease growth of human and murine pancreatic cancer in vitro and in vivo.[@R73] JNK may be involved in the regulation of tight junctions, including tricellulin expression and the barrier function in normal pancreatic duct epithelial cells and may be a potential therapeutic target for pancreatic cancer.

Conclusion
==========

Using hTERT-HPDE cells, we indicated that the expression of tight junction molecules and the barrier function in normal HPDE cells were regulated by various factors including PKC and JNK signal pathways ([Table 1](#T1){ref-type="table"}). It is necessary to investigate the detailed regulation of tight junctions in normal HPDE cells via other signal transduction pathways as Hedgehog and Wnt/β-catenin. It is also important that the regulation of MARVEL family members, including tricellulin and marvelD3, be further investigated and compared with that of the claudin family in normal pancreatic duct epithelial cells.[@R74] The profile of tight junctions and the signaling in normal human pancreas may be potential diagnostic or therapeutic targets in inflammation and cancer of pancreas.

This work was supported by the Pancreas Research Foundation of Japan and the Ministry of Education, Culture, Sports, Science and Technology and the Ministry of Health, Labour and Welfare of Japan.

Previously published online: [www.landesbioscience.com/journals/tissuebarriers/article/24894](http://www.landesbioscience.com/journals/tissuebarriers/article/24894/)

01/17/2013

04/28/2013

05/01/2013

The authors declare no conflicts of interest.
